Bayer
100 Bayer Boulevard
Whippany
New Jersey
07981
United States
804 articles with Bayer
-
Bayer has transformed its pipeline by acquiring multiple cell and gene therapy companies, paving the way for life-saving and life-altering therapies for patients with different disease types.
-
Bayer and Mammoth Biosciences forged a strategic collaboration potentially valued at more than $1 billion. The partnership grants Bayer access to Mammoth’s CRISPR technology to develop in vivo gene-editing therapies.
-
Vipergen Establishes Research Partnership with Bayer to Discover Novel Compoundsfor Pharmaceuticals and More Sustainable Crop Protection Solutions
12/21/2021
Vipergen announced today the signing of a multi-target research agreement with Bayer to discover novel small-molecule lead compounds for development of pharmaceuticals and more sustainable crop protection solutions.
-
Bayer Consumer Health Division Announces Clinical Research Study Findings Evaluating Naproxen Sodium vs. an Opioid Combination in Acute Postsurgical Dental Pain
12/17/2021
Bayer Consumer Health Division announced today its clinical research study, "Analgesic efficacy of naproxen sodium versus hydrocodone/acetaminophen in acute postsurgical dental pain: a randomized, double-blind, placebo-controlled trial" was published online in the Postgraduate Medicine journal.
-
Mythic Therapeutics has roared out of the gate with a $103 million Series B financing round that will support “safer and smarter” next generation of antibody-drug conjugates (ADCs).
-
Phase III Investigational Trial of NUBEQA® (darolutamide) in Combination with Docetaxel and Androgen Deprivation Therapy (ADT) Meets Primary Endpoint of Significantly Increasing Overall Survival (OS) in Patients with mHSPC
12/3/2021
The Phase III ARASENS trial investigating the use of the oral androgen receptor inhibitor NUBEQA® in metastatic hormone-sensitive prostate cancer has met its primary endpoint.
-
Bayer has high hopes of driving its prostate cancer drug into blockbuster status, meaning over $1 billion in annual sales. This week's ARASENS trial results should help pave the road.
-
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
12/3/2021
ARASENS trial with darolutamide in combination with docetaxel and androgen deprivation therapy meets primary endpoint of significantly increasing overall survival in patients with metastatic hormone-sensitive prostate cancer
-
Subtle Medical and Bayer Collaborate to Advance Deep Learning Research to Harness the Power of AI in Medical Imaging
11/28/2021
Subtle Medical, a leading healthcare technology company, and Bayer, a leading life science company with extensive expertise from diagnosis to care, announced a collaboration to explore opportunities to utilize AI to aid in image acquisition in radiology.
-
CStone forged a licensing agreement with Jiangsu Hengrui Pharmaceuticals that grants the company access to a monoclonal antibody aimed at multiple forms of cancer.
-
Bayer Focuses on Farmers and Drives Innovation into 2022
11/11/2021
Harvest is a time for North American farmers to reflect on the past season’s successes and challenges, while looking ahead to what’s next.
-
Clinical Catch-Up: November 1-5
11/8/2021
The first week of November was marked by numerous clinical trial announcements. Here’s a look. -
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
-
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA® (finerenone)
10/27/2021
Bayer to present new analyses adding to the depth of knowledge on the cardiovascular and renal outcomes of KERENDIA ® (finerenone)
-
Bayer fuels leading market positions in Crop Science through delivery of unmatched innovation
10/19/2021
Bayer today announced continued progress in delivering customer-focused, sustainable agricultural innovation in an update with investors.
-
Ensoma Taps Gene Therapy Leader as First CEO
10/11/2021
After guiding BlueRock Therapeutics and its potential Parkinson’s disease stem cell therapy into the clinic and to a $1 billion acquisition by Bayer, Emile Nuwaysir is taking on gene therapy startup Ensoma as CEO. -
Clinical Catch-Up: September 20-24
9/27/2021
There was still some carryover from the European Society of Medical Oncology Congress 2021, but there was plenty of other clinical trial news last week. Here’s a look. -
Clinical Catch-Up: September 13-17
9/20/2021
With a conference the size of ESMO, it’s impossible to cover all the exciting news, but here are many of the highlights. Here’s a look. -
Biogen and Samsung Bioepis Heat Up the Lucrative AMD Market with First Biosimilar Approval
9/20/2021
Three weeks after snagging approval in the UK, the U.S. FDA approved Samsung Bioepis and Biogen’s biosimilar drug. Byooviz is the first Lucentis copycat biologic to hit the market.